PMID- 33657257
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20220118
IS  - 1440-1827 (Electronic)
IS  - 1320-5463 (Linking)
VI  - 71
IP  - 4
DP  - 2021 Apr
TI  - Biological categories of neuroblastoma based on the international neuroblastoma 
      pathology classification for treatment stratification.
PG  - 232-244
LID - 10.1111/pin.13085 [doi]
AB  - The International Neuroblastoma Pathology Classification (INPC), which 
      distinguishes a favorable histology (FH) and an unfavorable histology (UH), is 
      one of the most powerful prognostic factors in patients with neuroblastoma. FH 
      that shows spontaneous regression or age-appropriate tumor 
      differentiation/maturation, is common in infants and has mutual interaction with 
      Schwann cells via the NGF/NTRK1 pathway and gain of whole chromosome 17. In 
      contrast, UH is prevalent in older children and is molecularly heterogeneous. 
      MYCN amplification is the most frequent genomic abnormality in tumors with UH. 
      MYCN-amplified tumors demonstrate characteristic histology, the same as 
      MYC-positive neuroblastoma. Chromosome 1pLOH is often associated with MYCN 
      amplification, but on the other hand, chromosome 11qLOH rarely occurs in 
      combination with MYCN amplification. 11qLOH has an inferior prognostic impact in 
      UH without MYCN amplification. The high expression of ALK protein is a negative 
      prognostic factor in both ALK mutated or amplified tumors and FH, but not in UH. 
      Abnormal maintenance/elongation of telomeres; overexpression of telomerase 
      reverse transcriptase (TERT) and the alternative lengthening of telomeres (ALT) 
      phenotype due to ATRX mutation, are another molecular event in UH. The INPC, 
      incorporating immunohistochemistry for MYCN, MYC, ALK, TERT and ATRX, represents 
      a practical and implementable approach to create the biological category for the 
      future management of patients with this unique disease.
CI  - (c) 2021 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
FAU - Nakazawa, Atsuko
AU  - Nakazawa A
AUID- ORCID: 0000-0002-9008-4281
AD  - Department of Clinical Research, Saitama Children's Medical Center, Saitama, 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210303
PL  - Australia
TA  - Pathol Int
JT  - Pathology international
JID - 9431380
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.7.49 (Telomerase)
RN  - EC 3.6.4.12 (X-linked Nuclear Protein)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/genetics/metabolism
MH  - Biomarkers, Tumor/genetics
MH  - Cell Differentiation
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Immunohistochemistry
MH  - Infant
MH  - Mutation
MH  - N-Myc Proto-Oncogene Protein/genetics/metabolism
MH  - *Neuroblastoma/classification/genetics/pathology
MH  - *Prognosis
MH  - Schwann Cells/pathology
MH  - Telomerase/genetics
MH  - Telomere/pathology
MH  - X-linked Nuclear Protein/genetics
OTO - NOTNLM
OT  - ALK
OT  - MYCN
OT  - genome
OT  - histology
OT  - immunohistochemistry
OT  - neuroblastoma
OT  - prognosis
EDAT- 2021/03/04 06:00
MHDA- 2022/01/19 06:00
CRDT- 2021/03/03 17:11
PHST- 2020/12/06 00:00 [received]
PHST- 2021/01/27 00:00 [accepted]
PHST- 2021/03/04 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
PHST- 2021/03/03 17:11 [entrez]
AID - 10.1111/pin.13085 [doi]
PST - ppublish
SO  - Pathol Int. 2021 Apr;71(4):232-244. doi: 10.1111/pin.13085. Epub 2021 Mar 3.